Thermo Fisher Scientific Inc. acquires Olink Holding AB (2024)

Deal facts

Buyer: Thermo Fisher Scientific Inc.
Target: Olink Holding AB
Deal value: Not disclosed
Announced: 2 February 2024
Status: In review
Sector: Healthcare
Country: Sweden
Consideration: Not stated

Sources

UK_CMA_GOVUK

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

2 Feb 2024CMA Phase 1 launched
Thermo Fisher Scientific / Olink merger inquiry
The CMA has investigated and cleared the anticipated acquisition by Thermo Fisher Scientific Inc. of Olink Holding AB. Statutory timetable Phase 1 Action 30 July 2024 Decision published 8 July 2024 Decision announced 10 May 2024 Launch of merger inquiry 2 February 2024 to 23 February 2024 Invitation to comment Phase 1 CMA clearance decision
UK CMA

OpinionExit Mode editorial

We see a clear strategic signal in Thermo Fisher Scientific Inc's decision to acquire Olink Holding AB, announced on 2024-02-02. This cross-border transaction between a US giant and a Swedish target in the healthcare sector is not merely an expansion of product lines; it is a deliberate move to consolidate proteomics capabilities within a single global platform. The deal remains in review, which is the expected first step for any acquisition of this magnitude involving US and EU entities. For the SME founder watching from the sidelines, this highlights how global players are actively seeking to absorb niche, high-tech innovators to secure their long-term position in complex diagnostic markets.

The regulatory path ahead is the immediate focus. Because Olink is based in Sweden and Thermo Fisher is American, this deal will face scrutiny under both US and EU competition laws. We expect the CMA and the European Commission to examine whether this consolidation reduces competition in the protein analysis space. The "in_review" status confirms that regulators are already assessing potential anti-trust thresholds and market concentration. Founders must understand that a strategic fit does not guarantee a smooth clearance. Change-of-control covenants and specific regulatory conditions will likely dictate the final terms, regardless of the initial agreement between the parties. The absence of a disclosed value in the announcement is typical for deals still navigating this complex approval process, but it does not diminish the strategic intent.

Our view is that the structure of this deal underscores the importance of regulatory readiness before signing. The healthcare sector is heavily scrutinised, and cross-border deals often trigger extended review periods that can delay closing or force divestitures. We advise the SME founder to treat regulatory clearance as a primary deal mechanic, not a formality. Do not assume that a strategic buyer will absorb all regulatory risk without shifting the burden back to the seller through indemnities or escrow arrangements. You must prepare your data and compliance records to withstand a rigorous examination of your market share and customer overlap.

The specific action you should take this week is to map your customer base against your potential acquirer's existing portfolio to identify any immediate competition concerns. If you are in a similar position to Olink, run a preliminary anti-trust check on your top ten clients to see if they overlap significantly with your target buyer. This simple step will reveal whether your deal faces a high risk of regulatory blockage or if you can proceed with a clearer path to completion.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More strategic acquisition deals More from Thermo Fisher Scientific Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 July 2026CompletedHealthcare

GSK plc to acquire Nuvalent, Inc

GSK plc has agreed to acquire Nuvalent, Inc in a strategic acquisition valued at $10.6 billion. The transaction, announced and completed on 15 July 2026, involves full c…

Buyer: GSK plc
Target: Nuvalent, Inc
Deal value: USD 10,600,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

14 July 2026CompletedHealthcare

Volex plc to acquire Kepler SignalTek Ltd

Volex plc has agreed to acquire Kepler SignalTek Ltd, a healthcare sector business based in the United Kingdom. The strategic acquisition was announced and completed on…

Buyer: Volex plc
Target: Kepler SignalTek Ltd
Deal value: USD 89,400,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

2 July 2026CompletedHealthcare

Lixte Biotechnology Holdings, Inc. to acquire Nomad Transportable Power Systems, Inc.

Lixte Biotechnology Holdings, Inc. has agreed to acquire Nomad Transportable Power Systems, Inc. in a strategic acquisition within the Healthcare sector. The transaction…

Buyer: Lixte Biotechnology Holdings, Inc.
Target: Nomad Transportable Power Systems, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

30 June 2026Firm intentionHealthcare

Public Company Management Corporation to acquire Physicians Capital Management Corporation

Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…

Buyer: Public Company Management Corporation
Target: Physicians Capital Management Corporation
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history